001360 — Samsung Pharm Co Income Statement
0.000.00%
- KR₩147bn
- KR₩107bn
- KR₩52bn
Annual income statement for Samsung Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 44,566 | 48,269 | 54,901 | 51,832 | 51,955 |
Cost of Revenue | |||||
Gross Profit | 9,399 | 10,451 | 9,282 | 24,619 | 22,973 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 54,879 | 66,803 | 75,487 | 75,379 | 78,035 |
Operating Profit | -10,313 | -18,534 | -20,586 | -23,547 | -26,080 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 7,087 | -39,877 | -40,276 | -25,093 | -23,675 |
Provision for Income Taxes | |||||
Net Income After Taxes | 6,885 | -39,877 | -40,276 | -25,093 | -24,812 |
Net Income Before Extraordinary Items | |||||
Net Income | 6,885 | -39,877 | -40,276 | -25,093 | -24,812 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 6,885 | -39,877 | -40,276 | -25,093 | -24,812 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 164 | -464 | -494 | -210 | -264 |
Dividends per Share |